- Home
- SMTI vs MGNX Comparison
SMTI vs MGNX Comparison
Compare SMTI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTI
- MGNX
- Stock Information
- Founded
- SMTI 1982
- MGNX 2000
- Country
- SMTI United States
- MGNX United States
- Employees
- SMTI N/A
- MGNX N/A
- Industry
- SMTI Medical/Dental Instruments
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- SMTI Health Care
- MGNX Health Care
- Exchange
- SMTI Nasdaq
- MGNX Nasdaq
- Market Cap
- SMTI 288.2M
- MGNX 257.3M
- IPO Year
- SMTI N/A
- MGNX 2013
- Fundamental
- Price
- SMTI $33.01
- MGNX $3.17
- Analyst Decision
- SMTI Buy
- MGNX Hold
- Analyst Count
- SMTI 1
- MGNX 10
- Target Price
- SMTI $44.00
- MGNX $7.17
- AVG Volume (30 Days)
- SMTI 36.4K
- MGNX 506.1K
- Earning Date
- SMTI 11-12-2024
- MGNX 11-05-2024
- Dividend Yield
- SMTI N/A
- MGNX N/A
- EPS Growth
- SMTI N/A
- MGNX N/A
- EPS
- SMTI N/A
- MGNX N/A
- Revenue
- SMTI $78,056,873.00
- MGNX $141,329,000.00
- Revenue This Year
- SMTI $29.95
- MGNX $174.73
- Revenue Next Year
- SMTI $19.68
- MGNX N/A
- P/E Ratio
- SMTI N/A
- MGNX N/A
- Revenue Growth
- SMTI 24.66
- MGNX 16.68
- 52 Week Low
- SMTI $26.00
- MGNX $2.95
- 52 Week High
- SMTI $43.25
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- SMTI 34.95
- MGNX 41.22
- Support Level
- SMTI $31.13
- MGNX $3.10
- Resistance Level
- SMTI $34.22
- MGNX $3.45
- Average True Range (ATR)
- SMTI 1.80
- MGNX 0.20
- MACD
- SMTI -0.63
- MGNX -0.01
- Stochastic Oscillator
- SMTI 12.98
- MGNX 17.24
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).